


Reference Data

(Consolidated Financial Results for Q3 FY2016)



Daiichi-Sankyo

January 31, 2017

Daiichi Sankyo Co., Ltd.

<http://www.daiichisankyo.com>

Contents

1.	Consolidated Statement of Profit or Loss	P1
2.	Revenue of Global Products	P2
3.	Revenue by Business Units and Products	P3
4.	Consolidated Statement of Financial Position	P6
5.	Consolidated Statement of Cash Flows	P8
6.	Number of Employees	P9
7.	Capital Expenditure, Depreciation and Amortization	P9
8.	Summary of Product Outlines	P10
9.	Quarterly Data	P11
10.	Historical Data	P16
11.	Major R&D Pipeline (Innovative pharmaceuticals)	P20

1. Consolidated Statement of Profit or Loss

JPY Bn	FY2015 Q3 YTD		FY2016 Q3 YTD					FY2016						
	to revenue	Results	to revenue	Results	(vs. Forecast (%))	YoY	YoY (%)	to revenue	Forecast (as of Oct.)	to revenue	Forecast (as of Jan.)	vs. Forecast (as of Oct.)	YoY	YoY (%)
Revenue	100.0%	758.6	100.0%	734.4	(77.3%)	-24.2	-3.2%	100.0%	920.0	100.0%	950.0	30.0	-36.4	-3.7%
Cost of sales	31.3%	237.7	32.9%	241.7	(76.0%)	4.0	+1.7%	33.4%	307.0	33.5%	318.0	11.0	-0.6	-0.2%
(excl. Special items)	31.8%	241.2	32.9%	241.7		0.5	+0.2%							
(Special items)	-0.5%	-3.5	-	-		3.5	-							
Gross Profit	68.7%	520.8	67.1%	492.7	(78.0%)	-28.2	-5.4%	66.6%	613.0	66.5%	632.0	19.0	-35.8	-5.4%
SG&A expenses	30.6%	232.3	30.0%	220.5	(70.0%)	-11.8	-5.1%	34.0%	313.0	33.2%	315.0	2.0	-13.8	-4.2%
(excl. Special items)	30.9%	234.4	28.6%	209.9		-24.5	-10.5%							
(Special items)	-0.3%	-2.1	1.4%	10.6		12.7	-							
R&D expenses	18.2%	138.1	19.5%	143.5	(69.3%)	5.4	+3.9%	21.7%	200.0	21.8%	207.0	7.0	-1.7	-0.8%
(excl. Special items)	18.2%	137.8	19.5%	143.5		5.6	+4.1%							
(Special items)	0.0%	0.3	-	-		-0.3	-							
Operating Profit	19.8%	150.4	17.5%	128.7	(117.0%)	-21.7	-14.4%	10.9%	100.0	11.6%	110.0	10.0	-20.4	-15.7%
(Operating Profit before Special items)	19.1%	145.1	19.0%	139.3		-5.8	-4.0%							
Financial income/expenses		-4.9		3.5		8.4								
Share of profit or loss of investments accounted for using the equity method		-0.1		0.2		0.3								
Profit before tax	19.2%	145.4	18.0%	132.4	(120.4%)	-13.0	-9.0%	10.9%	100.0	11.6%	110.0	10.0	-12.4	-10.1%
Income taxes		36.1		45.1		9.0	+24.9%							
Profit for the year	14.4%	109.3	11.9%	87.3		-22.0	-20.1%							
Profit attributable to owners of the Company	14.6%	110.7	12.0%	88.2	(126.0%)	-22.5	-20.4%	7.1%	65.0	7.4%	70.0	5.0	-12.3	-14.9%

Forex impact: -40.8
(USD: -25.8, EUR: -7.6, ASCA: -7.5)

Forex impact: -10.1
(USD: -6.6, EUR: -1.0, ASCA: -2.5)

Forex impact: -14.7
(USD: -7.2, EUR: -4.7, ASCA: -2.8)

Forex impact: -8.5
(USD: -7.7, EUR: -0.6)

Forex impact: -7.6
(USD: -4.3, EUR: -1.3, ASCA: -2.0)

Improvement in forex gains/losses
FY2015:
Expenses relating to sale of Sun Pharma shares etc.

Decrease in R&D tax credit

Tax rate	24.8%	34.1%
Overseas sales ratio	44.3%	39.1%
Currency Rate (Average)		
USD/JPY	121.70	106.68
EUR/JPY	134.37	118.09

	FY2015 Q3 YTD	FY2016 Q3 YTD
Cost of Sales	Gain on sales of subsidiary / Gain on sales of fixed assets -3.5	
SG&A expenses	Restructuring costs in US 6.1	Restructuring costs 10.6
	Gain on sales of fixed assets -8.2	
R&D expenses	Restructuring costs in R&D 0.3	
Total	-5.3	10.6

	Currency Rate (Average)	
	USD	EUR
	102.67	107.51
	114.11	118.57

Annual impact of one yen change

	Forecast	
	USD	EUR
Revenue	2.2 JPY Bn	0.6 JPY Bn
Operating Profit	0.2 JPY Bn	minor

*At the time of disclosure of this report, the audit/review procedures for financial statements are in progress in accordance with the Financial Instruments and Exchange Act.

***Special items** : Items having a transitory and material impact on operating profit are defined as "Special items". Specifically, gains and losses related to: sale of fixed assets, restructuring, impairment, litigation, etc. amounting to 1 billion JPY or more are defined as "Special items".

2. Revenue of Global Products

JPY Bn	FY2015 Q3 YTD		FY2016 Q3 YTD				FY2016				
	Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast (as of Oct.)	Forecast (as of Jan.)	vs. Forecast (as of Oct.)	YoY	YoY (%)	
Olmesartan antihypertensive agent	228.5	179.1	(80.7%)	-49.4	-21.6%	216.0	222.0	6.0	-62.1	-21.9%	
Olmotec (JPN)	60.5	54.1	(78.4%)	-6.4	-10.5%	68.0	69.0	1.0	-4.9	-6.6%	
Rezaltas (JPN)	14.1	13.6	(75.6%)	-0.5	-3.5%	19.0	18.0	-1.0	-0.2	-0.9%	
Benicar/Benicar HCT incl. AG (US)	63.1	44.9	(83.1%)	-18.2	-28.9%	54.0	54.0	0.0	-25.5	-32.0%	
Azor (US)	15.7	9.0	(89.5%)	-6.7	-42.9%	8.0	10.0	2.0	-9.7	-49.3%	
Tribenzor (US)	9.6	7.1	(88.3%)	-2.5	-26.5%	6.0	8.0	2.0	-4.4	-35.5%	
Olmotec/Olmotec Plus (EU)	24.9	18.5	(83.9%)	-6.4	-25.8%	21.0	22.0	1.0	-10.8	-33.0%	
Sevikar (EU)	12.1	9.6	(79.8%)	-2.5	-20.7%	11.0	12.0	1.0	-4.5	-27.1%	
Sevikar HCT (EU)	7.4	6.6	(82.6%)	-0.8	-11.3%	8.0	8.0	0.0	-1.6	-16.9%	
Other subsidiaries, export, etc	21.1	15.8	(75.2%)	-5.3	-25.0%	21.0	21.0	0.0	-0.6	-2.7%	
Prasugrel antiplatelet agent	24.0	31.2	-	7.2	+30.0%	not disclosed	not disclosed	-	-	-	
Effient alliance revenue (US)	16.4	16.5	-	0.1	+0.6%	not disclosed	not disclosed	-	-	-	
Efient (EU)	3.3	6.1	-	2.8	+84.3%	not disclosed	not disclosed	-	-	-	
Efient (JPN)	3.3	7.8	(71.2%)	4.6	+138.8%	10.0	11.0	1.0	6.1	+124.6%	
Other subsidiaries, export, etc	1.0	0.7	-	-0.2	-24.4%	not disclosed	not disclosed	-	-	-	
Edoxaban anticoagulant agent	10.5	26.0	(70.8%)	15.4	+146.6%	35.3	36.7	1.4	21.7	+144.3%	
Lixiana (JPN)	9.6	17.9	(71.6%)	8.3	+86.5%	25.0	25.0	0.0	12.0	+92.6%	
Savaysa (US)	0.3	1.4	(70.4%)	1.1	+384.2%	1.6	2.0	0.4	1.6	+344.5%	
Lixiana (EU)	0.7	6.1	(68.2%)	5.5	+837.8%	8.0	9.0	1.0	7.5	+482.3%	
Other subsidiaries	-	0.6	(77.8%)	0.6	-	0.7	0.7	0.0	0.7	-	

3. Revenue by Business Units and Products (1)

JPY Bn	FY2015 Q3 YTD		FY2016 Q3 YTD				FY2016				
	Results		Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast (as of Oct.)	Forecast (as of Jan.)	vs. Forecast (as of Oct.)	YoY	YoY (%)
Japan	377.5		390.2	(77.3%)	12.8	+3.4%	500.0	505.0	5.0	10.3	+2.1%
Nexium	ulcer treatment	62.0	67.4	(81.2%)	5.5	+8.8%	83.0	83.0	0.0	0.6	+0.7%
Olmotec	antihypertensive agent	60.5	54.1	(78.4%)	-6.4	-10.5%	68.0	69.0	1.0	-4.9	-6.6%
Memary	Alzheimer's disease treatment	32.7	36.3	(74.2%)	3.7	+11.2%	51.0	49.0	-2.0	6.6	+15.5%
Loxonin	anti-inflammatory analgesic	38.2	29.3	(79.2%)	-8.9	-23.4%	37.0	37.0	0.0	-11.1	-23.1%
Tenelia	type 2 diabetes mellitus inhibitor	11.9	19.7	(75.7%)	7.8	+65.5%	28.0	26.0	-2.0	9.5	+57.2%
Lixiana	anticoagulant agent	9.6	17.9	(71.6%)	8.3	+86.5%	25.0	25.0	0.0	12.0	+92.6%
Rezaltas	antihypertensive agent	14.1	13.6	(75.6%)	-0.5	-3.5%	19.0	18.0	-1.0	-0.2	-0.9%
Pralia	treatment for osteoporosis	9.0	13.3	(78.1%)	4.3	+47.1%	16.0	17.0	1.0	4.5	+36.5%
Ranmark	treatment for bone complications caused by bone metastases from tumors	9.4	10.6	(81.6%)	1.3	+13.4%	13.0	13.0	0.0	0.6	+4.9%
Inavir	anti-influenza treatment	2.5	7.9	(56.5%)	5.4	+211.8%	13.0	14.0	1.0	-0.0	-0.2%
Cravit	synthetic antibacterial agent	14.6	12.0	(85.8%)	-2.6	-17.7%	13.0	14.0	1.0	-4.4	-23.8%
Omnipaque	contrast medium	13.2	11.1	(85.5%)	-2.1	-16.0%	12.0	13.0	1.0	-3.9	-22.9%
Urief	treatment for dysuria	9.0	8.9	(80.8%)	-0.2	-1.7%	11.0	11.0	0.0	-0.8	-7.0%
Artist	treatment for hypertension, angina pectoris and chronic heart failure	12.1	8.5	(77.3%)	-3.6	-29.7%	11.0	11.0	0.0	-4.1	-27.0%
Mevalotin	antihyperlipidemic agent	10.8	8.3	(82.8%)	-2.5	-23.2%	10.0	10.0	0.0	-3.4	-25.6%
Efient	antiplatelet agent	3.3	7.8	(71.2%)	4.6	+138.8%	10.0	11.0	1.0	6.1	+124.6%
Daiichi Sankyo Espha products		14.2	15.7	-	1.5	+10.8%	not disclosed	not disclosed	-	-	-
Vaccines business		30.0	31.2	-	1.3	+4.2%	not disclosed	not disclosed	-	-	-
Daiichi Sankyo Healthcare (OTC)		39.9	51.9	(78.6%)	12.0	+30.1%	65.0	66.0	1.0	12.6	+23.7%

3. Revenue by Business Units and Products (2)

JPY Bn	FY2015 Q3 YTD		FY2016 Q3 YTD				FY2016				
	Results		Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast (as of Oct.)	Forecast (as of Jan.)	vs. Forecast (as of Oct.)	YoY	YoY (%)
Daiichi Sankyo, Inc. (US)	145.5		115.8	(80.4%)	-29.7	-20.4%	132.0	144.0	12.0	-41.1	-22.2%
Olmesartan antihypertensive agent	88.4		60.9	(84.6%)	-27.5	-31.1%	68.0	72.0	4.0	-39.6	-35.5%
Benicar/Benicar HCT incl. AG	63.1		44.9	(83.1%)	-18.2	-28.9%	54.0	54.0	0.0	-25.5	-32.0%
Azor	15.7		9.0	(89.5%)	-6.7	-42.9%	8.0	10.0	2.0	-9.7	-49.3%
Tribenzor	9.6		7.1	(88.3%)	-2.5	-26.5%	6.0	8.0	2.0	-4.4	-35.5%
Welchol hypercholesterolemia treatment/ type 2 diabetes mellitus inhibitor	37.7		32.2	(78.5%)	-5.5	-14.6%	36.0	41.0	5.0	-7.4	-15.3%
Effient antiplatelet agent	16.4		16.5	-	0.1	+0.6%	not disclosed	not disclosed	-	-	-
Savaysa anticoagulant agent	0.3		1.4	(70.4%)	1.1	+384.2%	1.6	2.0	0.4	1.6	+344.5%
Movantik opioid-induced constipation treatment	1.3		2.9	-	1.6	+128.0%	not disclosed	not disclosed	-	-	-
Luitpold Pharmaceuticals, Inc. (US)	69.0		64.3	(73.0%)	-4.8	-6.9%	83.0	88.0	5.0	-3.0	-3.3%
Venofer treatment for iron deficiency anemia	24.4		21.2	(75.9%)	-3.1	-12.9%	25.0	28.0	3.0	-3.2	-10.3%
Injectafer treatment for iron deficiency anemia	12.9		17.2	(71.7%)	4.3	+33.8%	24.0	24.0	0.0	5.4	+28.8%
Daiichi Sankyo Europe GmbH	58.1		54.4	(77.7%)	-3.7	-6.3%	66.0	70.0	4.0	-7.8	-10.0%
Olmesartan antihypertensive agent	44.4		34.6	(82.5%)	-9.7	-22.0%	40.0	42.0	2.0	-16.9	-28.7%
Olmetec/Olmetec Plus	24.9		18.5	(83.9%)	-6.4	-25.8%	21.0	22.0	1.0	-10.8	-33.0%
Sevikar	12.1		9.6	(79.8%)	-2.5	-20.7%	11.0	12.0	1.0	-4.5	-27.1%
Sevikar HCT	7.4		6.6	(82.6%)	-0.8	-11.3%	8.0	8.0	0.0	-1.6	-16.9%
Effient antiplatelet agent	3.3		6.1	-	2.8	+84.3%	not disclosed	not disclosed	-	-	-
Lixiana anticoagulant agent	0.7		6.1	(68.2%)	5.5	+837.8%	8.0	9.0	1.0	7.5	+482.3%
Asia, South and Central America (ASCA)	62.6		52.5	(73.9%)	-10.1	-16.2%	70.0	71.0	1.0	-4.3	-5.8%
Daiichi Sankyo China	24.8		23.5	-	-1.2	-5.0%	not disclosed	not disclosed	-	-	-
Daiichi Sankyo Taiwan	4.0		3.7	-	-0.2	-5.4%	not disclosed	not disclosed	-	-	-
Daiichi Sankyo Korea	7.2		6.3	-	-0.8	-11.8%	not disclosed	not disclosed	-	-	-
Daiichi Sankyo Thailand	2.9		1.9	-	-1.0	-34.9%	not disclosed	not disclosed	-	-	-
Daiichi Sankyo Brasil Farmacêutica	6.7		6.8	-	0.2	+2.4%	not disclosed	not disclosed	-	-	-
Daiichi Sankyo Venezuela	7.1		0.1	-	-7.0	-98.2%	not disclosed	not disclosed	-	-	-

3. Revenue by Business Units and Products (3)

[Reference] Revenue in Local Currency

USD Mn

	FY2015 Q3 YTD Results	FY2016 Q3 YTD				FY2016				
		Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast (as of Oct.)	Forecast (as of Jan.)	vs. Forecast (as of Oct.)	YoY	YoY (%)
Daiichi Sankyo, Inc. (US)	1,196	1,086	(81.1%)	-110	-9.2%	1,286	1,339	54	-201	-13.0%
Olmesartan antihypertensive agent	727	571	(85.3%)	-156	-21.4%	662	670	7	-259	-27.9%
Benicar/Benicar HCT incl. AG	519	421	(83.8%)	-98	-18.9%	526	502	-24	-159	-24.1%
Azor	129	84	(90.2%)	-45	-34.8%	78	93	15	-71	-43.4%
Tribenzor	79	66	(89.0%)	-13	-16.2%	58	74	16	-29	-28.0%
Welchol hypercholesterolemia treatment/ type 2 diabetes mellitus inhibitor	310	302	(79.1%)	-8	-2.6%	351	381	31	-21	-5.3%
Effient antiplatelet agent	135	155	-	20	+14.7%	not disclosed	not disclosed	-	-	-
Savaysa anticoagulant agent	2	13	(70.9%)	11	+452.3%	16	19	3	15	+396.7%
Movantik opioid-induced constipation treatment	10	27	-	17	+160.0%	not disclosed	not disclosed	-	-	-

USD Mn

Luitpold Pharmaceuticals, Inc. (US)	567	602	(73.6%)	35	+6.2%	808	819	10	61	+8.0%
Venofer treatment for iron deficiency anemia	200	199	(76.5%)	-1	-0.6%	243	260	17	1	+0.2%
Injectafer treatment for iron deficiency anemia	106	161	(72.3%)	56	+52.6%	234	223	-11	68	+43.9%

EUR Mn

Daiichi Sankyo Europe GmbH	432	460	(78.0%)	28	+6.6%	578	590	12	4	+0.6%
Olmesartan antihypertensive agent	330	293	(82.8%)	-37	-11.2%	351	354	4	-90	-20.3%
Olmetec/Olmetec Plus	185	156	(84.2%)	-29	-15.6%	184	186	2	-62	-25.1%
Sevikar	90	81	(80.1%)	-9	-9.7%	96	101	5	-23	-18.5%
Sevikar HCT	55	56	(82.9%)	1	+1.0%	70	67	-3	-5	-7.0%
Effient antiplatelet agent	24	51	-	27	+109.7%	not disclosed	not disclosed	-	-	-
Lixiana anticoagulant agent	5	52	(68.4%)	47	+967.0%	70	76	6	64	+551.1%

4. Consolidated Statement of Financial Position

<Assets>

JPY Bn

	Mar. 2016	Dec. 2016	vs. Mar. 2016
Assets			
Current assets			
Cash and cash equivalents	222.2	197.0	-25.2
Trade and other receivables	248.8	280.8	32.1
Other financial assets	493.8	562.4	68.6
Inventories	144.3	159.4	15.2
Other current assets	15.2	14.8	-0.4
Subtotal	1,124.2	1,214.4	90.2
Assets held for sale	1.1	2.7	1.6
Total current assets	1,125.3	1,217.1	91.8
Non-current assets			
Property, plant and equipment	250.2	244.6	-5.6
Goodwill	78.7	80.6	1.9
Intangible assets	210.4	222.0	11.6
Investments accounted for using the equity method	1.2	1.4	0.2
Other financial assets	168.2	152.8	-15.4
Deferred tax assets	55.7	59.2	3.4
Other non-current assets	10.9	9.3	-1.6
Total non-current assets	775.3	769.8	-5.4
Total assets	1,900.5	1,986.9	86.4
* Liquidity on hand	714.7	758.6	43.8
Debt with interest	203.6	282.1	78.5
Net Cash	511.1	476.4	-34.7

Issuance of bonds +100.0,
Acquisition of own shares -50.1,
Payment of dividends -43.9,
Payment of income taxes -22.3,
Repayment of borrowings -20.0

Amortization

Acquisition +20.3, Amortization -11.5,
Forex gain +3.8

Evaluation loss -14.0

<Liabilities and equity>

JPY Bn

	Mar. 2016	Dec. 2016	vs. Mar. 2016	
Liabilities				
Current liabilities				
Trade and other payables	241.8	210.9	-30.9	
Bonds and borrowings	20.0	-	-20.0	Repayment of borrowings
Other financial liabilities	0.8	0.5	-0.3	
Income taxes payable	53.9	80.4	26.5	
Provisions	28.3	45.2	16.9	
Other current liabilities	34.8	22.2	-12.6	
Subtotal	379.7	359.3	-20.4	
Liabilities directly associated with assets held for sale	-	0.2	0.2	
Total current liabilities	379.7	359.5	-20.2	
Non-current liabilities				
Bonds and borrowings	181.0	280.5	99.5	Issuance of bonds
Other financial liabilities	9.1	7.7	-1.5	
Post employment benefit liabilities	14.0	15.0	1.0	
Provisions	12.3	12.4	0.1	
Deferred tax liabilities	33.7	33.9	0.2	
Other non-current liabilities	37.2	51.5	14.4	
Total non-current liabilities	287.3	401.0	113.7	
Total liabilities	667.0	760.5	93.5	
Equity				
Equity attributable to owners of the Company				
Share capital	50.0	50.0	-	
Capital surplus	103.9	103.8	-0.2	
Treasury shares	-64.2	-114.1	-50.0	Acquisition -50.0 (20 million shares)
Other components of equity	146.7	143.6	-3.1	
Retained earnings	994.9	1,042.6	47.7	Profit for the period +88.2, Payment of dividends -43.9
Total equity attributable to owners of the Company	1,231.4	1,225.8	-5.6	
Non-controlling interests				
Non-controlling interests	2.1	0.6	-1.5	
Total equity	1,233.5	1,226.4	-7.1	
Total liabilities and equity	1,900.5	1,986.9	86.4	

5. Consolidated Statement of Cash Flows

JPY Bn

	FY2015 Q3 YTD	FY2016 Q3 YTD	YoY
Cash flows from operating activities			
Profit before tax	145.4	132.4	-13.0
Depreciation and amortization	33.0	33.6	0.6
(Increase) decrease in receivables and payables	-52.0	-60.5	-8.5
Others, net	-4.2	-2.9	1.3
Income taxes paid	-29.3	-22.3	7.0
Net cash flows from operating activities	93.0	80.3	-12.7
Cash flows from investing activities			
Net (increase) decrease in time deposits and securities	-243.1	-69.5	173.6
(Acquisition of) proceeds from sales of fixed assets	-49.3	-37.0	12.3
Proceeds from sale of subsidiary	7.0	-	-7.0
Net (increase) decrease in investment securities	374.6	8.6	-366.1
Others, net	-10.4	2.9	13.3
Net cash flows from investing activities	78.8	-94.9	-173.7
Cash flows from financing activities			
Net (increase) decrease in borrowings	-20.0	-20.0	0.0
Proceeds from bonds and borrowings	-	100.0	100.0
Purchase of treasury shares	-50.2	-50.1	0.1
Dividends paid	-48.5	-43.9	4.6
Others, net	-1.0	-0.9	0.1
Net cash flows from financing activities	-119.8	-14.9	104.9
Net increase (decrease) in cash and cash equivalents	52.0	-29.6	-81.6
Cash and cash equivalents at the beginning of the period	189.4	222.2	32.8
Effect of exchange rate changes on cash and cash equivalents	-1.3	4.4	5.7
Cash and cash equivalents at the end of the period	240.1	197.0	-43.1
* Free cash flows (Cash flows from operating activities and investing activities)	171.8	-14.7	-186.5

FY2015: Increase in time deposits and securities

FY2015: Sale of Sun Pharma shares

FY2015: Acquisition of Im shares

6. Number of Employees

	Dec. 2015	Mar. 2016	Dec. 2016
	Results	Results	Results
Consolidated	16,075	15,249	15,124
Japan	8,602	8,589	8,728
North America	3,043	2,321	2,504
Europe	2,066	1,997	1,774
Others	2,364	2,342	2,118

7. Capital Expenditure, Depreciation and Amortization

	JPY Bn	FY2015 Q3 YTD Results	FY2015 Results	FY2016 Q3 YTD Results	FY2016 Forecast
Capital expenditure		20.3	23.3	22.1	33.0
Depreciation and amortization		33.0	44.3	33.6	46.0
Property, plant and equipment		21.0	28.0	22.2	-
Intangible assets		12.0	16.3	11.5	-

8. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance	Type of Alliance
Japan						
Nexium	esomeprazole	ulcer treatment	2011	AstraZeneca	AstraZeneca	Co-promotion (DS: Sales)
Olmetec	olmesartan	antihypertensive agent	2004	Daiichi Sankyo		
Memary	memantine	Alzheimer's disease treatment	2011	Merz		
Loxonin			1986	Daiichi Sankyo		
Loxonin Poultice	loxoprofen	anti-inflammatory analgesic	2006	Lead Chemical		
Loxonin Tape			2008	Lead Chemical		
Loxonin Gel			2010	Daiichi Sankyo		
Tenelia	teneligliptin	type 2 diabetes mellitus inhibitor	2012	Mitsubishi Tanabe	Mitsubishi Tanabe	Co-promotion (DS: Sales)
Lixiana	edoxaban	anticoagulant agent	2011	Daiichi Sankyo		
Rezaltas	olmesartan / azelnidipine	antihypertensive agent	2010	Daiichi Sankyo		
Pralia	denosumab	treatment for osteoporosis	2013	Amgen		
Ranmark	denosumab	treatment for bone complications caused by bone metastases from tumors	2012	Amgen		
Inavir	laninamivir	anti-influenza treatment	2010	Daiichi Sankyo		
Cravit	levofloxacin	synthetic antibacterial agent	1993	Daiichi Sankyo		
Omnipaque	iohexol	contrast medium	1987	GE Healthcare		
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei	Co-marketing
Artist	carvedilol	treatment for hypertension, angina pectoris and chronic heart failure	1993	Roche		
Mevalotin	pravastatin	antihyperlipidemic agent	1989	Daiichi Sankyo		
Efient	prasugrel	antiplatelet agent	2014	Daiichi Sankyo Ube Industries		
Daiichi Sankyo, Inc. (US)						
Olmesartan						
Benicar	olmesartan		2002			
Benicar HCT	olmesartan / hydrochlorothiazide	antihypertensive agent	2003	Daiichi Sankyo		
Azor	olmesartan / amlodipine		2007			
Tribenzor	olmesartan / amlodipine / hydrochlorothiazide		2010			
Welchol	colesevelam	hypercholesterolemia treatment/ type 2 diabetes mellitus inhibitor	2000	Genzyme		
Effient	prasugrel	antiplatelet agent	2009	Daiichi Sankyo Ube Industries	Lilly	Co-promotion (DS: Co-pro revenue)
Savaysa	edoxaban	anticoagulant agent	2015	Daiichi Sankyo		
Movantik	naloxegol	opioid-induced constipation treatment	2015	Nektar AstraZeneca	AstraZeneca	Co-promotion (DS: Co-pro revenue)
Luitpold Pharmaceuticals, Inc. (US)						
Venofer	iron sucrose injection	treatment for iron deficiency anemia	2000	Vifor Pharma	Fresenius	Co-marketing
Injectafer	ferric carboxymaltose injection	treatment for iron deficiency anemia	2013	Vifor Pharma		
Daiichi Sankyo Europe GmbH						
Olmesartan						
Olmetec	olmesartan		2002			
Olmetec Plus	olmesartan / hydrochlorothiazide	antihypertensive agent	2005	Daiichi Sankyo	Menarini Pfizer	Co-marketing
Sevikar	olmesartan / amlodipine		2009			
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010			
Efient	prasugrel	antiplatelet agent	2009	Daiichi Sankyo Ube Industries		
Lixiana	edoxaban	anticoagulant agent	2015	Daiichi Sankyo	Merck (MSD)	Co-marketing

<9. Quarterly Data>

1. Consolidated Statement of Profit or Loss

JPY Bn	FY2015	FY2015	FY2015	FY2015	FY2015				FY2016	FY2016	FY2016	FY2016	FY2016	
	Q1	Q2	Q3	Q4	to revenue	Results	YoY	YoY (%)	Q1	Q2	Q3	Q4	to revenue	Results
	Results	Results	Results	Results					Results	Results	Results	Results		
Revenue	238.4	240.4	279.8	227.9	100.0%	986.4	67.1	+7.3%	241.0	217.0	276.4		100.0%	734.4
Cost of sales	74.0	75.0	88.8	80.9	32.3%	318.6	-4.5	-1.4%	77.6	69.7	94.5		32.9%	241.7
(excl. Special items)	76.3	76.1	88.8	74.4	32.0%	315.6	29.7	+10.4%	77.6	69.7	94.5		32.9%	241.7
(Special items)	-2.4	-1.1	-	6.5	0.3%	3.0	-34.1	-91.8%	-	-	-		-	-
Gross Profit	164.5	165.4	191.0	147.0	67.7%	667.8	71.5	+12.0%	163.4	147.4	181.9		67.1%	492.7
SG&A expenses	71.6	72.8	87.8	96.5	33.3%	328.8	-2.4	-0.7%	69.5	72.2	78.8		30.0%	220.5
(excl. Special items)	75.6	77.1	81.7	84.6	32.3%	319.0	0.3	+0.1%	69.5	66.2	74.2		28.6%	209.9
(Special items)	-3.9	-4.3	6.1	11.9	1.0%	9.8	-2.8	-22.1%	-	6.0	4.6		1.4%	10.6
R&D expenses	43.7	44.7	49.8	70.5	21.2%	208.7	18.0	+9.4%	46.6	49.2	47.7		19.5%	143.5
(excl. Special items)	43.7	44.7	49.5	65.2	20.6%	203.0	16.8	+9.0%	46.6	49.2	47.7		19.5%	143.5
(Special items)	-	-	0.3	5.4	0.6%	5.6	1.2	+27.0%	-	-	-		-	-
Operating Profit	49.1	47.9	53.4	-20.0	13.2%	130.4	56.0	+75.2%	47.3	26.0	55.4		17.5%	128.7
(Operating Profit before Special items)	42.9	42.5	59.8	3.7	15.1%	148.9	20.3	+15.8%	47.3	32.0	60.0		19.0%	139.3
Financial income/expenses	-3.7	-2.1	1.0	-2.9		-7.7	-14.2		-1.9	0.7	4.6			3.5
Share of profit or loss of investments accounted for using the equity method	-0.2	-0.1	0.2	-0.2		-0.3	0.6		-0.2	-0.0	0.4			0.2
Profit before tax	45.2	45.6	54.6	-23.0	12.4%	122.4	42.5	+53.1%	45.2	26.7	60.5		18.0%	132.4
Income taxes	11.1	10.3	14.7	5.9		42.0	5.6	+15.4%	15.1	9.0	21.0			45.1
Profit for the year	34.1	35.3	39.9	-28.9	8.2%	80.4	36.8	+84.5%	30.1	17.7	39.5		11.9%	87.3
Profit attributable to owners of the Company	34.9	35.8	40.0	-28.4	8.3%	82.3	35.8	+77.1%	30.6	18.4	39.2		12.0%	88.2
Tax rate	24.6%	22.5%	27.0%	-25.5%		34.3%			33.4%	33.7%	34.7%			34.1%
Overseas sales ratio	46.8%	46.2%	40.6%	41.5%		43.7%			42.0%	37.9%	37.6%			39.1%
<u>Currency Rate (Average)</u>														
USD/JPY	121.37	121.80	121.70	120.14		120.14			108.25	105.35	106.68			106.68
EUR/JPY	134.16	135.07	134.37	132.57		132.57			122.17	118.22	118.09			118.09

<9. Quarterly Data>

2. Revenue of Global Products

JPY Bn	FY2015 Q1	FY2015 Q2	FY2015 Q3	FY2015 Q4	FY2015			FY2016 Q1	FY2016 Q2	FY2016 Q3	FY2016 Q4	FY2016
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
Olmesartan	75.6	71.9	80.9	55.7	284.1	-9.4	-3.2%	65.7	49.7	63.7		179.1
Olmetec (JPN)	18.5	17.7	24.3	13.4	73.9	-2.5	-3.2%	18.3	16.6	19.2		54.1
Rezaltas (JPN)	4.6	4.3	5.2	4.1	18.2	-0.2	-1.3%	4.7	4.2	4.8		13.6
Benicar/Benicar HCT incl. AG (US)	19.8	20.5	22.8	16.3	79.5	2.5	+3.2%	17.3	8.9	18.7		44.9
Azor (US)	5.8	4.6	5.2	4.1	19.7	1.5	+8.1%	3.3	2.5	3.1		9.0
Tribenzor (US)	3.1	3.2	3.3	2.8	12.4	1.1	+9.8%	2.5	2.1	2.5		7.1
Olmetec/Olmetec Plus (EU)	8.9	8.2	7.8	7.9	32.8	-4.9	-13.1%	7.7	5.9	4.8		18.5
Sevikar (EU)	4.5	4.1	3.5	4.4	16.5	-1.1	-6.3%	3.6	3.0	3.0		9.6
Sevikar HCT (EU)	2.5	2.2	2.8	2.2	9.6	-0.3	-2.7%	2.7	1.8	2.2		6.6
Other subsidiaries, export, etc	7.9	7.1	6.0	0.5	21.6	-5.4	-20.2%	5.6	4.7	5.5		15.8
Prasugrel	7.8	7.4	8.7	8.2	32.2	7.3	+29.4%	10.9	9.3	10.9		31.2
Effient alliance revenue (US)	5.2	5.4	5.8	4.3	20.7	3.2	+18.1%	6.0	4.9	5.7		16.5
Efient (EU)	1.1	1.1	1.1	2.1	5.4	0.6	+13.0%	2.3	1.9	1.9		6.1
Efient (JPN)	1.2	0.6	1.5	1.6	4.9	4.2	+613.5%	2.5	2.4	2.9		7.8
Other subsidiaries, export, etc	0.3	0.4	0.3	0.2	1.2	-0.7	-36.5%	0.2	0.2	0.4		0.7
Edoxaban	1.8	3.5	5.2	4.5	15.0	10.7	+251.1%	7.3	8.7	9.9		26.0
Lixiana (JPN)	2.1	3.2	4.2	3.4	13.0	9.4	+262.6%	5.5	6.0	6.4		17.9
Savaysa (US)	-0.3	0.1	0.5	0.2	0.4	-0.2	-35.6%	0.3	0.6	0.5		1.4
Lixiana (EU)	0.0	0.1	0.5	0.9	1.5	1.5	-	1.4	1.9	2.8		6.1
Other subsidiaries	-	-	-	0.0	0.0	0.0	-	0.1	0.3	0.2		0.6

3. Revenue by Business Units and Products (1)

JPY Bn	FY2015 Q1	FY2015 Q2	FY2015 Q3	FY2015 Q4	FY2015			FY2016 Q1	FY2016 Q2	FY2016 Q3	FY2016 Q4	FY2016
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
Japan	114.2	113.6	149.6	117.2	494.7	14.2	+2.9%	123.4	115.6	151.2		390.2
Nexium	19.1	19.6	23.3	20.4	82.4	13.1	+18.8%	21.0	21.0	25.4		67.4
Olmetec	18.5	17.7	24.3	13.4	73.9	-2.5	-3.2%	18.3	16.6	19.2		54.1
Memary	10.2	10.2	12.2	9.7	42.4	5.6	+15.3%	12.1	11.3	12.9		36.3
Loxonin	12.6	11.8	13.9	9.9	48.1	-1.4	-2.8%	10.3	8.5	10.5		29.3
Tenelia	2.4	3.0	6.6	4.6	16.5	9.0	+118.9%	6.7	5.1	7.9		19.7
Lixiana	2.1	3.2	4.2	3.4	13.0	9.4	+262.6%	5.5	6.0	6.4		17.9
Rezaltas	4.6	4.3	5.2	4.1	18.2	-0.2	-1.3%	4.7	4.2	4.8		13.6
Pralia	2.6	2.8	3.7	3.4	12.5	5.1	+70.1%	4.1	4.2	5.0		13.3
Ranmark	2.9	3.0	3.5	3.0	12.4	2.2	+22.0%	3.4	3.4	3.8		10.6
Inavir	0.0	0.0	2.5	11.5	14.0	-2.6	-15.4%	0.6	0.0	7.4		7.9
Cravit	4.6	4.4	5.6	3.8	18.4	-9.5	-34.0%	3.8	3.6	4.7		12.0
Omnipaque	4.2	4.2	4.8	3.6	16.9	-0.3	-1.9%	3.7	3.5	3.9		11.1
Urief	2.9	2.8	3.3	2.8	11.8	0.3	+2.8%	3.0	2.7	3.1		8.9
Artist	4.1	3.8	4.2	3.0	15.1	-3.0	-16.8%	3.1	2.6	2.8		8.5
Mevalotin	3.6	3.4	3.8	2.7	13.4	-2.7	-16.9%	2.9	2.5	2.8		8.3
Efient	1.2	0.6	1.5	1.6	4.9	4.2	+613.5%	2.5	2.4	2.9		7.8
Daiichi Sankyo Espha products	4.3	4.3	5.6	4.3	18.5	3.6	+23.9%	5.2	4.7	5.8		15.7
Vaccines business	6.4	8.0	15.6	6.8	36.8	4.6	+14.2%	6.6	8.0	16.6		31.2
Daiichi Sankyo Healthcare (OTC)	10.8	13.8	15.2	13.5	53.4	5.5	+11.6%	14.8	17.4	19.7		51.9

3. Revenue by Business Units and Products (2)

JPY Bn	FY2015 Q1	FY2015 Q2	FY2015 Q3	FY2015 Q4	FY2015			FY2016 Q1	FY2016 Q2	FY2016 Q3	FY2016 Q4	FY2016
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
Daiichi Sankyo, Inc. (US)	48.0	45.4	52.1	39.6	185.1	12.1	+7.0%	40.7	29.6	45.5		115.8
Olmesartan	28.8	28.3	31.3	23.2	111.6	5.1	+4.7%	23.2	13.5	24.3		60.9
Benicar/Benicar HCT incl. AG	19.8	20.5	22.8	16.3	79.5	2.5	+3.2%	17.3	8.9	18.7		44.9
Azor	5.8	4.6	5.2	4.1	19.7	1.5	+8.1%	3.3	2.5	3.1		9.0
Tribenzor	3.1	3.2	3.3	2.8	12.4	1.1	+9.8%	2.5	2.1	2.5		7.1
Welchol	13.5	10.6	13.5	10.7	48.4	1.0	+2.1%	10.0	9.5	12.7		32.2
Effient	5.2	5.4	5.8	4.3	20.7	3.2	+18.1%	6.0	4.9	5.7		16.5
Savaysa	-0.3	0.1	0.5	0.2	0.4	-0.2	-35.6%	0.3	0.6	0.5		1.4
Movantik	0.2	0.4	0.7	0.7	2.0	2.0	-	0.9	0.9	1.1		2.9
Luitpold Pharmaceuticals, Inc. (US)	21.5	24.9	22.6	22.0	91.0	33.6	+58.6%	22.0	19.8	22.5		64.3
Venofer	9.1	6.9	8.4	6.8	31.2	2.6	+9.2%	7.4	6.5	7.4		21.2
Injectafer	3.9	4.0	5.0	5.8	18.6	11.0	+143.9%	5.9	5.2	6.1		17.2
Daiichi Sankyo Europe GmbH	20.2	19.0	18.8	19.7	77.8	-5.7	-6.9%	20.4	16.5	17.4		54.4
Olmesartan	15.8	14.4	14.2	14.5	58.9	-6.3	-9.7%	14.0	10.7	10.0		34.6
Olmetec/Olmetec Plus	8.9	8.2	7.8	7.9	32.8	-4.9	-13.1%	7.7	5.9	4.8		18.5
Sevikar	4.5	4.1	3.5	4.4	16.5	-1.1	-6.3%	3.6	3.0	3.0		9.6
Sevikar HCT	2.5	2.2	2.8	2.2	9.6	-0.3	-2.7%	2.7	1.8	2.2		6.6
Effient	1.1	1.1	1.1	2.1	5.4	0.6	+13.0%	2.3	1.9	1.9		6.1
Lixiana	0.0	0.1	0.5	0.9	1.5	1.5	-	1.4	1.9	2.8		6.1
Asia, South and Central America (ASCA)	21.4	21.3	19.9	12.7	75.3	7.8	+11.6%	17.7	16.3	18.4		52.5
Daiichi Sankyo China	7.9	8.6	8.3	9.4	34.2	6.9	+25.1%	8.2	7.3	8.1		23.5
Daiichi Sankyo Taiwan	1.4	1.3	1.3	1.4	5.4	0.5	+10.5%	1.3	1.2	1.3		3.7
Daiichi Sankyo Korea	2.4	2.4	2.4	2.2	9.3	0.5	+5.2%	2.1	2.0	2.2		6.3
Daiichi Sankyo Thailand	0.8	1.0	1.1	1.2	4.1	0.4	+11.5%	0.6	0.5	0.8		1.9
Daiichi Sankyo Brasil Farmacêutica	2.6	1.9	2.1	1.4	8.1	-0.3	-3.1%	2.0	2.1	2.7		6.8
Daiichi Sankyo Venezuela	3.1	2.4	1.6	-6.9	0.2	-7.9	-98.0%	0.0	0.0	0.1		0.1

3. Revenue by Business Units and Products (3)

[Reference] Revenue in Local Currency

	FY2015 Q1	FY2015 Q2	FY2015 Q3	FY2015 Q4	FY2015			FY2016 Q1	FY2016 Q2	FY2016 Q3	FY2016 Q4	FY2016
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
USD Mn												
Daiichi Sankyo, Inc. (US)	396	371	429	345	1,540	-33	-2.1%	376	291	419		1,086
Olmesartan	237	232	257	202	929	-40	-4.2%	214	134	223		571
Benicar/Benicar HCT incl. AG	163	168	187	143	661	-39	-5.6%	160	89	172		421
Azor	48	38	43	35	164	-2	-1.1%	31	25	28		84
Tribenzor	26	26	27	24	103	1	+0.5%	23	20	23		66
Welchol	112	87	111	93	403	-29	-6.6%	92	92	117		302
Effient	43	44	48	38	173	13	+8.0%	55	48	52		155
Savaysa	-2	1	4	1	4	-3	-41.1%	3	6	5		13
Movantik	1	3	6	6	17	17	-	8	9	10		27
USD Mn												
Luitpold Pharmaceuticals, Inc. (US)	177	204	186	191	758	236	+45.2%	203	193	206		602
Venofer	75	57	69	59	260	-0	-0.1%	68	63	67		199
Injectafer	32	33	41	49	155	86	+123.2%	55	51	56		161
EUR Mn												
Daiichi Sankyo Europe GmbH	151	140	142	155	587	-15	-2.5%	167	145	148		460
Olmesartan	118	106	106	114	444	-25	-5.4%	114	94	85		293
Olmetec/Olmetec Plus	66	60	59	62	248	-24	-9.0%	63	52	41		156
Sevikar	33	30	27	34	124	-2	-1.9%	29	26	25		81
Sevikar HCT	18	16	21	17	73	1	+1.9%	22	16	18		56
Efient	8	8	8	16	41	6	+18.3%	19	17	16		51
Lixiana	0	1	4	7	12	12	-	12	16	24		52

<10. Historical Data>

1. Revenue of Global Products

	FY2011	FY2012	FY2013	FY2014	FY2015
JPY Bn	Results	Results	Results	Results	Results
Olmesartan	249.7	258.9	300.2	293.5	284.1
Olmetec (JPN)	80.9	78.3	79.1	76.3	73.9
Rezaltas (JPN)	13.5	16.9	18.5	18.4	18.2
Benicar/Benicar HCT (US)	71.3	73.2	85.9	77.0	79.5
Azor (US)	12.0	14.8	17.4	18.3	19.7
Tribenzor (US)	4.6	6.8	9.0	11.3	12.4
Olmetec/Olmetec Plus (EU)	36.6	32.6	44.5	37.8	32.8
Sevikar (EU)	11.0	10.8	13.5	17.6	16.5
Sevikar HCT (EU)	3.4	4.7	7.6	9.9	9.6
Other subsidiaries, export, etc	16.5	20.7	24.7	27.0	21.6
Prasugrel	10.9	14.4	22.3	24.9	32.2
Effient alliance revenue (US)	7.9	10.5	15.4	17.6	20.7
Efient (EU)	2.9	3.9	4.7	4.8	5.4
Efient (JPN)	-	-	-	0.7	4.9
Other subsidiaries, export, etc	-	-	2.2	1.9	1.2
Edoxaban	-	-	0.4	4.3	15.0
Lixiana (JPN)	-	-	0.4	3.6	13.0
Savaysa (US)	-	-	-	0.7	0.4
Lixiana (EU)	-	-	-	-	1.5
Other subsidiaries	-	-	-	-	0.0

2. Revenue by Business Units and Products (1)

	FY2011	FY2012	FY2013	FY2014	FY2015
JPY Bn	Results	Results	Results	Results	Results
Japan	409.8	442.5	486.0	480.5	494.7
Nexium	3.9	21.6	54.2	69.3	82.4
Olmetec	80.9	78.3	79.1	76.3	73.9
Memary	9.8	23.8	33.3	36.8	42.4
Loxonin	61.0	59.6	59.3	49.5	48.1
Tenelia	-	1.3	1.5	7.6	16.5
Lixiana	0.3	0.3	0.4	3.6	13.0
Rezaltas	13.5	16.9	18.5	18.4	18.2
Pralia	-	-	3.2	7.3	12.5
Ranmark	-	4.4	8.1	10.2	12.4
Inavir	10.7	11.1	13.4	16.6	14.0
Cravit	36.3	35.9	33.5	27.8	18.4
Omnipaque	23.5	20.2	19.7	17.2	16.9
Urief	11.0	11.1	11.4	11.5	11.8
Artist	24.5	22.4	22.4	18.1	15.1
Mevalotin	33.1	25.8	21.5	16.2	13.4
Efient	-	-	-	0.7	4.9
Daiichi Sankyo Espha products	9.9	11.1	12.5	14.9	18.5
Vaccines business	21.2	39.1	37.5	32.2	36.8
Daiichi Sankyo Healthcare (OTC)	45.9	47.1	48.1	47.8	53.4

2. Revenue by Business Units and Products (2)

	FY2011	FY2012	FY2013	FY2014	FY2015
JPY Bn	Results	Results	Results	Results	Results
Daiichi Sankyo, Inc. (US)	127.1	142.3	171.8	173.0	185.1
Olmesartan	87.9	94.9	112.3	106.6	111.6
Benicar/Benicar HCT	71.3	73.2	85.9	77.0	79.5
Azor	12.0	14.8	17.4	18.3	19.7
Tribenzor	4.6	6.8	9.0	11.3	12.4
Welchol	26.9	33.1	42.3	47.4	48.4
Effient	7.9	10.5	15.4	17.6	20.7
Savaysa	-	-	-	0.7	0.4
Movantik	-	-	-	-	2.0
Luitpold Pharmaceuticals, Inc. (US)	44.7	38.6	39.6	57.4	91.0
Venofer	24.8	23.6	24.9	28.6	31.2
Injectafer	-	-	1.3	7.6	18.6
Daiichi Sankyo Europe GmbH	70.2	64.4	83.9	83.5	77.8
Olmesartan	51.0	48.0	65.6	65.2	58.9
Olmetec/Olmetec Plus	36.6	32.6	44.5	37.8	32.8
Sevikar	11.0	10.8	13.5	17.6	16.5
Sevikar HCT	3.4	4.7	7.6	9.9	9.6
Efient	2.9	3.9	4.7	4.8	5.4
Lixiana	-	-	-	-	1.5
Asia, South and Central America (ASCA)	28.6	45.4	58.8	67.5	75.3
Daiichi Sankyo China	9.7	16.4	21.2	27.4	34.2
Daiichi Sankyo Taiwan	3.1	3.3	4.5	4.9	5.4
Daiichi Sankyo Korea	4.6	5.3	9.1	8.9	9.3
Daiichi Sankyo Thailand	1.2	1.4	2.5	3.7	4.1
Daiichi Sankyo Brasil Farmacêutica	5.5	6.6	7.5	8.4	8.1
Daiichi Sankyo Venezuela	4.2	6.7	6.9	8.1	0.2

2. Revenue by Business Units and Products (3)

[Reference] Revenue in Local Currency

	FY2011	FY2012	FY2013	FY2014	FY2015
	Results	Results	Results	Results	Results
USD Mn					
Daichi Sankyo, Inc. (US)	1,608	1,713	1,714	1,574	1,540
Olmesartan	1,112	1,142	1,120	969	929
Benicar/Benicar HCT	901	881	857	700	661
Azor	152	179	174	166	164
Tribenzor	58	82	90	103	103
Welchol	340	399	422	431	403
Effient	100	127	154	160	173
Savaysa	-	-	-	6	4
Movantik	-	-	-	-	17
USD Mn					
Luitpold Pharmaceuticals, Inc. (US)	566	465	395	522	758
Venofer	314	284	248	260	260
Injectafer	-	-	13	69	155
EUR Mn					
Daichi Sankyo Europe GmbH	644	601	624	602	587
Olmesartan	468	448	488	470	444
Olmetec/Olmetec Plus	336	304	331	272	248
Sevikar	101	100	100	127	124
Sevikar HCT	31	44	57	71	73
Efient	27	36	35	34	41
Lixiana	-	-	-	-	12

11. Major R&D Pipeline (Innovative pharmaceuticals)

As of January 2017

◆ Oncology (Late-stage pipeline products)

Generic Name/Project Code Number (Brand Name)	Class	Target indication	Region	Stage	Dosage Form	Partner	Target FY for approval/launch	Remarks
Denosumab/AMG 162 Ranmark (JP)	Anti-RANKL antibody	Breast cancer adjuvant	JP	P3	Injection	Amgen	2020	Additional indication
The fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation.								
Vemurafenib/PLX4032 Zelboraf	BRAF inhibitor	Melanoma adjuvant	US/EU	P3	Oral	-	-	Additional indication. Licensee Roche is conducting the study. Submission in 2017 is planned.
The molecular-targeted agent to inhibit BRAF V600E mutation.								
Tivantinib/ARQ 197	MET inhibitor	Hepatocellular cancer	US/EU	P3	Oral	ArQule, Inc.	2018	HCC with MET high patients
The molecular-targeted agent to inhibit HGF(hepatocyte growth factor) receptor, MET which has multiple roles in intracellular signal transductions such as cancer cell proliferation, angiogenesis, invasion, and apoptosis induction.								
Quizartinib/AC220	FLT3-ITD inhibitor	Acute myeloid leukemia	US/EU/Asia	P3	Oral	-	2018	Relapsed and refractory AML patients
			US/EU/Asia	P3			2021-	Newly diagnosed AML patients
			JP	P1			-	
Kinase inhibitor against a receptor-type tyrosine kinase, FLT3. Therapeutic effect for patients with acute myeloid leukemia harboring FLT3-ITD mutation is expected.								
Pexidartinib/PLX3397	CSF-1R/KIT/FLT3-ITD inhibitor	Tenosynovial Giant Cell Tumor (TGCT)	US/EU	P3	Oral	-	2019	Including pigmented villonodular synovitis
		Solid tumor	Asia	P1			-	Including TGCT
		Glioblastoma	US	P2			-	
		c-KIT Melanoma	Asia	P1/2			-	
		Melanoma, solid tumor	US	P1/2			-	Merck & Co., Inc.
The molecular-targeted agent to inhibit CSF-1R, KIT and FLT3-ITD. This agent is expected to reduce tumor cell proliferation and expansion of metastases.								
Nimotuzumab/DE-766	Anti-EGFR antibody	Gastric cancer	JP	P3	Injection	InnoCIMA b Pte Ltd	2020	
The humanized monoclonal antibody to target Epidermal Growth Factor Receptor(EGFR). This antibody is expected to be a best in class EGFR, safety against the skin toxicity and the efficacy comparable to the other antibodies.								
Patritumab/U3-1287	Anti-HER3 antibody	Head & neck cancer	EU	P2	Injection	-	-	
The fully human monoclonal antibody to target HER3, one of the Epidermal Growth Factor Receptor (EGFR) family of proteins. HER 3 is overexpressed in many tumors of epithelial origin and HER2/HER3 dimers and EGFR/HER3 dimers are expected more potent to induce tumor cell proliferation than homodimers of HER2 or EGFR.								
DS-1647(G47Δ)	Oncolytic HSV-1	Glioblastoma	JP	P2	Injection	ActiVec Inc.	-	Received SAKIGAKE Designation from MHLW Investigator Initiated Study is on-going
The third generation oncolytic herpes simplex virus type 1(HSV-1), genetically-engineered to restrict virus replication to tumor cells. This oncolytic virus therapy is expected equal or better safety and better efficacy profile compare to existing oncolytic virus.								

Underline: change after FY2016 Q2 Financial Announcement in October 2016

◆ Oncology (Early-stage pipeline products)

Generic Name/Project Code Number	Class	Target indication	Region	Stage	Partner	Target FY for approval/launch	Remarks
DS-3032	MDM2 inhibitor	Solid tumor, lymphoma	US/JP	P1	-	-	
		Leukemia	US	P1	-	-	
PLX7486	FMS/TRK inhibitor	Solid tumor	US	P1	-	-	
DS-8895	Anti-EPHA2 antibody	Solid tumor	JP	P1	-	-	
DS-8273	Anti-DR5 antibody	Solid tumor	US	P1	-	-	
PLX8394	BRAF inhibitor	Solid tumor, leukemia	US	P1	-	-	
DS-6051	NTRK/ROS1 inhibitor	Solid tumor	US/JP	P1	-	-	
DS-5573	Anti-B7-H3 antibody	Solid tumor	JP	P1	-	-	
PLX9486	KIT inhibitor	Solid tumor	US	P1	-	-	
DS-8201	Anti-HER2 antibody drug conjugate	Solid tumor	JP/US	P1	-	-	
U3-1784	Anti-FGFR4 antibody	Solid tumor	EU	P1	-	-	
DS-1123	Anti-FGFR2 antibody	Solid tumor	JP	P1	-	-	
DS-3201	EZH1/2 inhibitor	Non-Hodgkin's lymphoma	JP	P1	-	-	
PLX73086/AC708	CSF-1R inhibitor	Tenosynovial Giant Cell Tumor (TGCT)	US	P1	-	-	
PLX51107	BRD4 inhibitor	Hematologic malignancies	US	P1	-	-	
U3-1402	Anti-HER3 antibody drug conjugate	Solid tumor	JP	P1	-	-	

Underline: change after FY2016 Q2 Financial Announcement in October 2016

◆ **Cardiovascular-Metabolics (Late-stage pipeline products)**

Generic Name/Project Code Number (Brand Name)	Class	Target indication	Region	Stage	Dosage Form	Partner	Target FY for approval/launch	Remarks
Edoxaban/DU-176b Lixiana (JP) LIXIANA (EU, Asia) SAVAYSA (US)	Factor Xa inhibitor	Atrial fibrillation (AF)	ASCA etc.	Submitted Approved	Oral	-	-	BR (14/6*), CN(15/8) * means June 2014, ditto CA(16/11), TR(16/11), TH(16/12)
		Venous thromboembolism (VTE)	ASCA etc.	Submitted Approved			-	BR (14/6), CN(15/8) CA(16/11), TR(16/11), TH(16/12)
		Elderly patients with non-valvular atrial fibrillation	JP	P3			2021	Additional dosage and administration for elderly patients
The once daily oral anti coagulant (FXa inhibitor) discovered by Daiichi Sankyo. Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood.								
Prasugrel/CS-747	Anti-platelet agent	Ischemic stroke	JP	P3	Oral	Ube Industries	2017	Additional indication, phase 3 studies completed
Effient (US, Asia) Efient (JP, EU) The oral antiplatelet agent. Prasugrel helps to keep blood platelets from clumping together and developing a blockage in an artery.								
Esaxerenone/CS-3150	MR antagonist	Hypertension	JP	P3	Oral	Exelixis, Inc.	2019	-
		Diabetic nephropathy	JP	P2b			-	
The agent inhibits aldosterone binding to Mineralocorticoid Receptor(MR) which stimulate the sodium absorption into kidney. This agent is expected antihypertensive and organ-protective effect.								
DS-8500	GPR119 agonist	Diabetes	JP/US	P2	Oral	-	-	
The agent agonistically acts on GPR119 which is expressed in small intestine and spleen cells. This agent is expected to stimulate insulin secretion, and to lower blood glucose concentration.								

Underline: change after FY2016 Q2 Financial Announcement in October 2016

◆ **Cardiovascular-Metabolics (Early-stage pipeline products)**

Generic Name/Project Code Number	Class	Target indication	Region	Stage	Partner	Target FY for approval/launch	Remarks
DS-1040	TAFIa inhibitor	Acute ischemic stroke, Acute pulmonary embolism	-	P1	-	-	
DS-2330	Hyperphosphatemia treatment	Hyperphosphatemia in chronic kidney disease (CKD)	-	P1	-	-	
DS-9231/TS23	α 2 plasmin inhibitor-inactivating antibody	Thrombosis (cardiovascular diseases, ischemic stroke)	-	P1	Translational Sciences, Inc.	-	In-lisencing from Translational Sciences, Inc.
DS-9001	Anti-PCSK9 Anticalin-Albumod	Dyslipidemia	-	P1	-	-	Using technology of Pieris Pharmaceuticals, Inc. and Affibody AB

Underline: change after FY2016 Q2 Financial Announcement in October 2016

◆ Internal Medicine (Late-stage pipeline products)

Generic Name/Project Code Number (Brand Name)	Class	Target indication	Region	Stage	Dosage Form	Partner	Target FY for approval/launch	Remarks
CL-108	Opioid μ -receptor agonist combination	Acute pain	US	Submitted	Oral	Charleston Laboratories, Inc.	-	NDA was submitted in March 2016 by Charleston Laboratories, Inc., licensor and co-development partner
	Combination product of immediate-release promethazine, hydrocodone and acetaminophen. Reduction of opioid-induced nausea and vomiting (OINV) is expected.							
Hydromorphone/DS-7113	Opioid μ -receptor agonist	Cancer pain	JP	Submitted	Oral	-	-	NDA of oral formulation was submitted in March 2016 by Daiichi Sankyo Propharma Extended-release and immediate-release formulations
			JP	P3	Injection	-	2018	
Mirogabalin/DS-5565	$\alpha 2\delta$ ligand	Fibromyalgia	US/EU	P3	Oral	-	2019	The pain therapy agent to reduce the neurotransmitter release from nerve terminals. This agent is expected to show the good balanced efficacy and safety profile.
		Diabetic peripheral neuropathic pain	JP/Asia	P3			2018	
		Postherpetic neuralgia	JP/Asia	P3			2018	
Denosumab/AMG 162 Pralia (JP)	Anti-RANKL antibody	Rheumatoid arthritis	JP	Submitted	Injection	Amgen	-	Additional Indication, submitted in Sep 2016
CHS-0214	TNF α inhibitor	Rheumatoid arthritis	JP	P3	Injection	Coherus BioSciences, Inc.	2017	In preparation for submission
	Etanercept biosimilar							
Laninamivir/CS-8958 Inavir (JP)	Neuraminidase inhibitor	Influenza	US/EU	P2	Inhalation	-	-	Out-licensing with Biota
			JP	P3			-	Additional dosage form, nebulizer formulation

Underline: change after FY2016 Q2 Financial Announcement in October 2016

◆ Internal Medicine (Early-stage pipeline products)

Generic Name/Project Code Number	Class	Target indication	Region	Stage	Partner	Target FY for approval/launch	Remarks
DS-1971	Analgesic agent	Chronic pain	-	P1	-	-	
DS-1501	Anti-Siglec-15 antibody	Osteoporosis	US	P1	-	-	
DS-7080	Angiogenesis inhibitor	Neovascular age-related macular degeneration (AMD)	US	P1	-	-	
DS-2969	GyrB inhibitor	Clostridium difficile infection (CDI)	-	P1	-	-	
DS-5141	ENA oligonucleotide	Duchenne muscular dystrophy (DMD)	JP	P1/2	-	-	

Underline: change after FY2016 Q2 Financial Announcement in October 2016

◆ Vaccines

Generic Name/Project Code Number (Brand Name)	Class	Target indication	Region	Stage	Dosage Form	Partner	Target FY for approval/launch	Remarks
VN-100	Intradermal Seasonal Influenza Vaccine	Prevention of seasonal influenza	JP	Submitted	Injection*	Terumo Corporation	-	Submitted by Japan Vaccine in April 2015 * prefilled syringe
		The Vaccine is a pre-filled syringe type, intradermal influenza HA vaccine co-developed by four companies [Daiichi Sankyo, Terumo Corporation, Japan Vaccine and Kitasato Daiichi Sankyo Vaccine Co., Ltd.]. The intradermal injection device for this vaccine is developed by Terumo Corporation. This device, which offers a more easy-to-use, surefire method to administer the vaccine than current methods. The device is also expected to ease patient hesitation to be injected and lower the risk of damaging peripheral blood vessels and nerves within the subcutaneous tissue.						
VN-0107/MEDI3250	Live attenuated influenza vaccine	Prevention of seasonal Influenza	JP	Submitted	Nasal spray	AstraZeneca/ MedImmune	-	Submitted by Daiichi Sankyo in June 2016
		The US brand name of this vaccine is FluMist Quadrivalent that is a live attenuated influenza vaccine which is administered as a nasal spray and contains four protective strains.						
VN-0105	DPT-IPV/Hib vaccine	Prevention of pertussis, diphtheria, tetanus, poliomyelitis and Hib	JP	P3	Injection	Sanofi Pasteur	2019	Co-develop with Sanofi K.K.and KDSV
		A combination vaccine reconstituting Hib with precipitated and purified pertussis-diphtheria-tetanus-inactivated polio vaccine (Salk vaccine) vaccine launched in Japan, as 1st in the class of pentavalent vaccine (DPT-IPV/Hib).						
VN-0102/JVC-001	Measles-Mumps-Rubela vaccine	Prevention of Measles, Mumps and Rubela	JP	P1/2	Injection	-	-	Japan vaccine company is conducting the phase 1/2 study

Underline: change after FY2016 Q2 Financial Announcement in October 2016

◆ Stage-up (major changes from the FY2016 Q2 Financial Announcement in October 2016)

Generic Name/Project Code Number	Class	Target indication	Current region/stage	Remarks
Edoxaban	FXa inhibitor	Atrial fibrillation (AF)	ASCA etc. Approved	CA(16/11*), TR(16/11), TH(16/12) * means November 2016, ditto
		Venous thromboembolism (VTE)	ASCA etc. Approved	CA(16/11*), TR(16/11), TH(16/12)
Laninamivir	Neuraminidase inhibitor	Influenza	JP P3	Additional dosage form, nebulizer formulation. Started phase 3 study

